Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Uterine Cervix and/or Vulva
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Cervical cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 13 Sep 2005 New trial record.